Bevacizumab is the first antiangiogenic therapy to be approved in advanced adenocarcinoma lung in combination with chemotherapy. Dose used in different trial was different and varied from 7.5 mg/kg 3 weekly to 15 mg/kg every 3 weeks. Chemotherapy partner included paclitaxel carboplatin , pemetrexed carboplatin and gemcitabine cisplatin. Nintedanib is oral triple angiokinase (VEGFR, PDGFR A& B, FGFR1-3) inhibitor approved in European country in second line setting in combination with docetaxel based on results of lume-lung-1 in advanced adenocarcinoma lung. Ramucirumab is VEGFR-2 antagonist approved advanced stage carcinoma lung in both squamous and adenocarcinoma in combination with docetaxel at a dose of 10 mg/kg 3 weekly.